Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative
NCT ID: NCT03765775
Last Updated: 2018-12-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
20 participants
INTERVENTIONAL
2018-11-20
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer
NCT03766490
Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer
NCT05306847
Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations
NCT04790409
Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance
NCT06634667
Anlotinib Single Drug as the Maintenance Treatment for Advanced NSCLC
NCT03998085
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Anlotinib Hydrochloride+Sintilimab
Participants receive Sintilimab (IBI 308) 200 mg, administered as intravenous (IV) infusion on Day 1 of each 21-day cycle , Anlotinib 12mg, administered as PO on Day1-14 of each 21-day cycle until documented PD
Sintilimab
Participants receive Sintilimab(IBI 308) 200 mg, administered as intravenous (IV) infusion on Day 1 of each 21-day cycle
Anlotinib Hydrochloride
Participants receive Anlotinib 10 mg, administered as PO on Day 1-14 of each 21-day cycle
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sintilimab
Participants receive Sintilimab(IBI 308) 200 mg, administered as intravenous (IV) infusion on Day 1 of each 21-day cycle
Anlotinib Hydrochloride
Participants receive Anlotinib 10 mg, administered as PO on Day 1-14 of each 21-day cycle
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female patients aged 18-75 years old.
3. Has a histologically-confirmed or cytologically confirmed diagnosis of stage IV nonsquamous NSCLC.
Has confirmation that epidermal growth factor receptor (EGFR) mutation，with first-generation EGFR-TKIs drug resistance T790M negative .
4. Has measurable disease.
5. There is at least one target lesion that has not received radiotherapy in the past 3 months, and it can be accurately measured in at least one direction (the maximum diameter needs to be recorded) by magnetic resonance imaging (MRI) or computed tomography (CT), in which conventional CT is greater than 20mm or spiral CT is greater than 10mm.
6. Has a life expectancy of at least 3 months.
7. Has a performance status of 0 or 2 on the Eastern Cooperative Oncology Group (ECOG) Performance Status.
8. Has adequate organ function.
9. Patients with asymptomatic or mild brain metastasis may be enrolled.
10. If female of childbearing potential, is willing to use adequate contraception for the course of the study through 120 days after the last dose of study medication or through 180 days after last dose of chemotherapeutic agents.
11. If male with a female partner(s) of child-bearing potential, must agree to use adequate contraception starting with the first dose of study medication through 120 days after the last dose of study medication or through 180 days after last dose of chemotherapeutic agents.
Exclusion Criteria
2.ALK(Anaplastic Lymphoma kinase) positive. 3.Imaging (CT or MRI) showed that the tumor lesion invaded the central tumor of local large blood vessels;Or there is obvious pulmonary cavitation or necrotic tumor.
4.History and complications
1. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.(patients with brain metastasis who have completed treatment 14 days before enrollment and have stable symptoms can be included in the group, but they need to be confirmed as having no symptoms of cerebral hemorrhage by brain MRI, CT).
2. Have Participated in other clinical studies or less than 4 weeks before the end of treatment in the previous clinical study.
3. Other active malignancies requiring concurrent treatment.
4. Known history of prior malignancy except if participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy, except for successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, in situ cervical cancer, or other in situ cancers.
5. Patients who have not recovered to level 1 or lower of NCI-CTCAE4.0 （The Common Terminology Criteria for Adverse Events 4.0）after previous systemic anti-tumor treatment with anti-tumor treatment-related adverse reactions (except hair loss).
6. Abnormal coagulation function (INR(international normalized ratio) \>1.5 or PT(prothrombin time) \> ULN+4 s or APTT(activated partial thromboplastin time ) \> 1.5ULN), with bleeding tendency or receiving thrombolytic or anticoagulant treatment.
7. Is expected to require any other form of antineoplastic therapy while on study.
8. Received a live-virus vaccination within 30 days of planned start of study medication.
9. Known sensitivity to any component of Anlotinib or Sintilimab.
10. Has active autoimmune disease that has required systemic treatment in past 2 years.
11. Is on chronic systemic steroids.
12. Has an active infection requiring therapy.
13. Has known history of Human Immunodeficiency Virus (HIV).
14. Has known active Hepatitis B or C.
15. Has known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the trial.
16. Is a regular user (including "recreational use") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol).
17. Has symptomatic ascites or pleural effusion.
18. Has interstitial lung disease or a history of pneumonitis that required oral of IV glucocorticoids to assist with management.
19. Two or more combination therapies for hypertension that are still uncontrollable (systolic blood pressure greater than 140 mmHg or diastolic blood pressure greater than 90 mmHg).
20. Arteriovenous thrombosis events occurred within 12 months before enrollment, such as cerebrovascular accidents (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism.
21. clinically significant hemoptysis occurred within 3 months before enrollment (hemoptysis \> 50ml daily);Or bleeding symptoms of significant clinical significance or with a clear bleeding tendency, such as gastrointestinal bleeding, bleeding gastric ulcer, baseline stool occult blood ++ or above, or suffering from vasculitis.
22. factors that significantly affect oral drug absorption, such as inability to swallow, chronic diarrhea and intestinal obstruction.
23. Is pregnant or breastfeeding, or expecting to conceive or father children prior to 120 days after the last dose of study medication or through 180 days after last dose of chemotherapeutic agents.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First Hospital of Shijiazhuang City
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yan Zhang, M.D.
Role: STUDY_CHAIR
The First Hospital of Shijiazhuang
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Hospital of Shijiazhuang
Shijiazhuang, Hebei, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LC01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.